全文获取类型
收费全文 | 202390篇 |
免费 | 14099篇 |
国内免费 | 6463篇 |
专业分类
耳鼻咽喉 | 2676篇 |
儿科学 | 2717篇 |
妇产科学 | 2984篇 |
基础医学 | 29591篇 |
口腔科学 | 4394篇 |
临床医学 | 22087篇 |
内科学 | 33802篇 |
皮肤病学 | 4800篇 |
神经病学 | 14352篇 |
特种医学 | 9956篇 |
外国民族医学 | 53篇 |
外科学 | 24568篇 |
综合类 | 11288篇 |
现状与发展 | 24篇 |
一般理论 | 46篇 |
预防医学 | 11601篇 |
眼科学 | 6070篇 |
药学 | 19143篇 |
67篇 | |
中国医学 | 5494篇 |
肿瘤学 | 17239篇 |
出版年
2024年 | 333篇 |
2023年 | 2086篇 |
2022年 | 5756篇 |
2021年 | 8257篇 |
2020年 | 4989篇 |
2019年 | 5659篇 |
2018年 | 6541篇 |
2017年 | 5350篇 |
2016年 | 6279篇 |
2015年 | 8870篇 |
2014年 | 10719篇 |
2013年 | 11155篇 |
2012年 | 16715篇 |
2011年 | 16759篇 |
2010年 | 9834篇 |
2009年 | 8099篇 |
2008年 | 11410篇 |
2007年 | 10915篇 |
2006年 | 10385篇 |
2005年 | 9741篇 |
2004年 | 7765篇 |
2003年 | 6859篇 |
2002年 | 5827篇 |
2001年 | 4784篇 |
2000年 | 4533篇 |
1999年 | 4165篇 |
1998年 | 2181篇 |
1997年 | 1914篇 |
1996年 | 1456篇 |
1995年 | 1344篇 |
1994年 | 1145篇 |
1993年 | 804篇 |
1992年 | 1333篇 |
1991年 | 1186篇 |
1990年 | 1107篇 |
1989年 | 963篇 |
1988年 | 833篇 |
1987年 | 766篇 |
1986年 | 578篇 |
1985年 | 575篇 |
1984年 | 391篇 |
1983年 | 276篇 |
1982年 | 173篇 |
1981年 | 219篇 |
1980年 | 157篇 |
1979年 | 285篇 |
1978年 | 183篇 |
1976年 | 146篇 |
1974年 | 167篇 |
1973年 | 137篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. 总被引:1,自引:0,他引:1
Beta-adrenergic receptor density on T cells from healthy humans is greatest on suppressor cells (CD8+, CD28-) and the effect of catecholamines, secreted by the sympathetic nervous system, predominates on this subset. The sympathetic skin response, a measure of sympathetic nervous system function, is absent in most patients with chronic progressive multiple sclerosis (MS). We measured beta-adrenergic receptor density on suppressor cells, cytotoxic cells, and monocytes from patients with chronic progressive MS and healthy control subjects. Control receptor density on suppressor cells was 2.8 +/- 0.3 fmol/10(6) cells versus a density of 5.1 +/- 0.7 fmol/10(6) cells for patients. Cytotoxic cell (CD8+, CD28+) receptor density was 1.4 +/- 0.4 fmol/10(6) cells in control subjects and 0.9 +/- 0.3 fmol/10(6) cells in the patients. Monocytes displayed beta-adrenergic receptor densities of 2.6 +/- 0.4 fmol/10(6) cells in normal individuals and 2.7 +/- 0.4 fmol/10(6) cells in the patient group. CD8 lymphocyte beta-adrenergic receptor densities in patients with relapsing-remitting and those with stable MS were not different from control values, yet were significantly less than the values for patients with chronic progressive MS. We find that mononuclear cells from healthy control subjects and patients with chronic progressive MS proliferate in response to 200 units/ml of recombinant human interleukin-2 (IL-2) similarly. However, IL-2 treatment increased beta-adrenergic receptor density on normal mononuclear cells, but failed to increase it on mononuclear cells from patients with chronic progressive MS.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
22.
23.
24.
25.
26.
27.
28.
29.
30.
Su Jin Lee Young Keun On Eun Jeong Lee Joon Young Choi Byung-Tae Kim Kyung-Han Lee 《Journal of nuclear medicine》2008,49(8):1277-1282
Vascular 18F-FDG uptake marker represents inflammation in atherosclerotic lesions, but whether inflammation can be reversed by risk-modifying interventions has not, to our knowledge, been demonstrated. In this study, we evaluated the change of vascular 18F-FDG uptake in response to lifestyle intervention on serial PET/CT scans and further assessed how the findings relate to atherogenic risk reduction. METHODS: A total of 60 healthy adults underwent 18F-FDG PET/CT scans and atherogenic risk-factor assessment at baseline and again after 17.1 +/- 8.3 mo of practicing lifestyle modification. The PET/CT images were evaluated for the presence of vascular 18F-FDG lesions, and vessel-to-blood-pool 18F-FDG ratios were measured. Indices from summed ratios of positive lesions were compared and correlated to atherogenic risk factors. RESULTS: At follow-up, significant reductions in diastolic blood pressure (P < 0.05), total cholesterol (P < 0.05), and low-density lipoprotein level (P < 0.05) and an increase in high-density lipoprotein (HDL) level (P < 0.0001) were demonstrated. On the initial PET/CT scan, 50 of 60 subjects showed 1 or more 18F-FDG-positive lesions (5.9 +/- 5.0/subject), leading to a total of 352 vascular sites. On follow-up, 18F-FDG-positive lesions were significantly reduced to 2.1 +/- 2.2 sites per subject (P < 0.0001) and a total of 124 sites (64.8% reduction). Follow-up 18F-FDG-positive rates were significantly reduced for the aorta and iliac arteries. In addition, significant reductions in the whole-body 18F-FDG index from 1.39 +/- 1.23 to 0.53 +/- 0.59 (P < 0.0001) and carotid 18F-FDG index from 0.08 +/- 0.16 to 0.03 +/- 0.06 (P = 0.01) were shown. The whole-body 18F-FDG index correlated with total cholesterol (P < 0.05) and HDL level (P < 0.05), and the magnitude of reduction in the 18F-FDG index closely correlated to the amount of increase in plasma HDL level (P = 0.005). CONCLUSION: Our study demonstrated that vascular 18F-FDG uptake is reversed in response to atherogenic risk reduction by lifestyle intervention and that the magnitude of improvement correlates to increases in plasma HDL levels. Thus, serial 18F-FDG PET/CT may be useful for monitoring improvements in the inflammatory component of atherosclerotic lesions in response to risk modification. 相似文献